If you are wondering whether Bristol-Myers Squibb is quietly becoming a value opportunity or just a classic value trap, you ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after an analyst at ...

Fintel reports that on December 12, 2025, Guggenheim upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Neutral ...

Fintel reports that on December 12, 2025, Morgan Stanley maintained coverage of Bristol-Myers Squibb Company - Preferred Security (OTCPK:BMYMP) with a Underweight recommendation. Analyst Price ...

Neutral sector-focused overview describing factual commentary surrounding Bristol Myers Squibb within the wider ...

Bristol-Myers Squibb faces patent cliff risks despite strong drug revenues and a 4.8% yield. Click here to read my latest analysis of BMY stock.

Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even ...

Shares of drugmaker Bristol Myers Squibb were up almost 6% as of Wednesday afternoon, despite a delay in a late-stage study ...

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...

By Jonathan Stempel NEW YORK, Dec 1 (Reuters) - A U.S. judge on Monday rejected Bristol Myers Squibb's bid to dismiss a $6.7 ...

BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company ...